Complix, a Hasselt, Belgium-based biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabody™ (CPAB) based oncology therapeutics, received a €0.5m grant.
The Flanders Government through the Flemish Agency for Innovation & Entrepreneurship (VLAIO) provided the grant.
The company will use the funds to further develop its CPAB platform addressing targets within the nucleus of cancer cells.
Complix is a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabody[TM] (CPAB) based therapeutics against a number of intracellular targets, that play an important role in oncology.
Complix is able to design and generate CPABs that can address targets both in the cytosol and the nucleus of the cancer cell.
The company has an ongoing strategic collaboration with Merck & Co to develop novel CPAB based therapeutics against two selected intracellular cancer targets. Under the terms of this collaboration, which was recently expanded, Complix is eligible to receive up to $280 million in upfront and development and regulatory milestones as well as tiered mid-single digit royalties on global sales revenues.
Since its foundation in 2008, Complix has raised more than €27 million through several rounds of venture financing.